May 7, 2021 at 12:44 PM
Shares5
Victoria Nugent, partner and co-chair of Cohen Milstein Sellers & Toll PLLC
“Half a century almost, sliced the green like a lawnmower… / I’m coin-based, basically cryptocurrency Scarface / Join us, there’s got to be more of us.”
This week, I had the opportunity to catch up with Victoria Nugent, who was recently appointed the co-chair of Cohen Milstein Sellers & Toll PLLC’s Consumer Protection Practice Group. It’s been almost four years to the day we last connected.
Ever since we met, I have admired Victoria and her mission as a consumer advocate. It is evident when speaking with her just how passionate she is about consumer protections, women’s representation in leadership positions, and the practice of law.
ADVERTISEMENT
ADVERTISEMENT
Attys Denied $12M Fees From Modest At Best Facebook Deal
Law360 (May 6, 2021, 11:02 PM EDT) A California federal judge on Thursday declined a bid for $12 million in fees for lawyers representing a class of Facebook users that reached a nonmonetary settlement over a data breach suit, calling the outcome modest as best and cosmetic at worst.
U.S. District Judge William Alsup gave final approval to the settlement but nixed the present bid for fees from counsel at Tadler Law LLP, Cohen Milstein Sellers & Toll PLLC and Morgan & Morgan Complex Litigation Group, instead tasking a special master with reviewing the attorneys billing information and reducing fees to a reasonable amount, noting that they would.
The forces behind the Hollywood "inclusion rider" initiative announced Wednesday they have created a new and "reimagined" rider aimed at further diversifying film and television production crews while increasing accountability measures.
Endeavor Content, #ChangeHollywood Launch New Inclusion Rider hollywoodreporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hollywoodreporter.com Daily Mail and Mail on Sunday newspapers.
Health
your username
3 hours ago The Fourth Circuit on Tuesday vacated a district court judgment that dismissed a class-action complaint lodging claims of federal and state antitrust law violations against Actelion Pharmaceuticals Ltd., Actelion Pharmaceuticals US Inc., and Janssen Research & Development LLC, remanding the matter back to the District of Maryland for further proceedings.
The class action originated over allegations that Actelion “extended its patent monopoly” for pulmonary artery hypertension drug Tracleer beyond the patent expiration date, the court explained, “through illegitimate means” in order to corner the market of generic pharmaceuticals and inflate Tracleer prices. The plaintiff class, led by the Mayor and City Council of Baltimore and Government Employees Health Association, alleged that they had to pay “supracompetitive prices” for the drug for at least three years after the Tracleer patent expired because no generic competitors were able t